Volume 14, Number 2—February 2008
Cost-effectiveness of Antiviral Stockpiling and Near-Patient Testing for Potential Influenza Pandemic
|Treatment program||Pandemic influenza cases (millions)||Pandemic influenza deaths (millions)||Discounted NHS costs (million £)||Discounted QALY loss (millions)||Incremental cost per QALY (£)|
*NHS, National Health Service; QALY, quality-adjusted life years; CFR, case-fatality ratio.
†Cost per QALY gained over no intervention program.
‡Cost per QALY gained over treat-only program.
- Page created: July 08, 2010
- Page last updated: July 08, 2010
- Page last reviewed: July 08, 2010
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)